🔗 Share this article

While the United States continues making sweeping revisions to its immunization recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by questioning COVID-19 shots in the pandemic and has focused upon potential deaths after COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Program

Public health authorities planned to reveal sweeping changes to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of step with many the international standard with little proof for benefit. The announcement has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the office this calendar year.

Consolidating Power at the Regulatory Body

This interim role might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has repeatedly called for ending certain childhood shot schedules in the US to become more in line with Denmark's approach, a nation with universal health coverage and a population about the size of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.

Questions Over Background

The appointee has no apparent track record in drug development, approval processes or leadership, which has been customary for past leaders of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a sizeable institution. She is not an expert in drug approvals.”

Former directors of the center would “understand regulatory frameworks and the research of drug development”, said Janet Woodcock. “Objectively, she lacks the kind of background that previous people who ran CBER have had.”

CDER has an immense workload at the agency, the former commissioner emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division approves thousands of generic drugs. There is also a biologic copycat branch, over-the-counter program and so forth, and each of these must be looked after,” Dr. Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a major leadership element to the job, which manages over 5,000 staff members. “It is a enormous management job, if you perform it correctly,” the former official concluded.

Response and Disputed Policies

Regarding questions about Dr. Høeg's credentials and whether this appointment represents more teamwork among regulatory chiefs on vaccines, a representative said that the “questions are based on flawed premises”.

“This background matches the duties of her role,” the spokesperson said, pointing to the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's new priority voucher program, a disputed rapid drug-approval program that reportedly concerned her predecessors. “How are these drugs being picked for this voucher program? Who takes the calls?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards more relaxed rules of all drugs, with the exception of vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, track record, some experts said. She authored a study using unverified crowd-sourced reports to estimate the rate of myocarditis following COVID-19 vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the new administration included changing rules for new vaccines and halting “unnecessary” immunizations, she said post-election on a audio program. At the agency, Høeg has reportedly floated the idea of preventing teenage boys from getting Covid vaccinations.

“She is an thorough ideologue who starts off with her preconceived notions and works backwards to accommodate the science in a extremely disingenuous, dishonest manner,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|